BeiGene's Brukinsa Fails In Head-To-Head But Hope Remains For Rare Indication
Signs Of Benefit Vs Imbruvica
Days after bagging a US approval for its first global new drug, BeiGene was dealt a blow as its BTK inhibitor Brukinsa showed no significant superiority over class leader Imbruvica in Waldenström's macroglobulinemia, although the Chinese company remains hopeful for a possible approval.
